Ganoderic acid B8
IUPAC name: (6R)-2-methyl-4-oxo-6-[(3S,5R,7S,10S,13R,14R,15S,17R)-3,7,15-trihydroxy-4,4,10,13,14-pentamethyl-11-oxo-1,2,3,5,6,7,12,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl]heptanoic acid
CAS Number: CID_21632956
Class: Terpenoid
Mushrooms contain this compound
1 mushrooms
MushID |
Thai name |
Common name |
Scientific name |
Family |
1 |
เห็ดหลินจือ |
Lingzhi |
Ganoderma lucidum ( Curtis ) P. Karst. |
Ganodermataceae |
2D Structure
Compound Properties
SMILES
O=C(C[C@H](C(=O)O)C)C[C@H]([C@H]1C[C@@H]([C@@]2([C@]1(C)CC(=O)C1=C2[C@@H](O)C[C@@H]2[C@]1(C)CC[C@@H](C2(C)C)O)C)O)C
Physicochemical Properties
Formula |
C30H46O7 |
Molecular wieght(g/mol) |
518.68 |
Num. of Heavy atoms |
37 |
Num. of Aromatic Heavy atoms |
0 |
Fraction Csp3 |
0.83 |
Num. of Rotatable bonds |
6 |
Num. of H-bond acceptors |
7 |
Num. of H-bonds donors |
4 |
Molar Refractivity |
142.01 |
TPSA (square Angstrom) |
132.13 |
Lipophilicity
iLOGP |
2.84 |
XLOGP3 |
2.50 |
WLOGP |
3.92 |
MLOGP |
2.34 |
Silicos-IT LOGP |
4.40 |
Consensus LOGP |
3.20 |
Water Solubility
ESOL |
|
LogS |
-4.23 |
Solubility(mg/ml) |
3.02E-02 |
Solubility(mol/l) |
5.82E-05 |
Class |
Moderately soluble |
Ali |
|
LogS |
-4.92 |
Solubility(mg/ml) |
6.23E-03 |
Solubility(mol/l) |
1.20E-05 |
Class |
Moderately soluble |
Silicos-IT |
|
LogS |
-4.27 |
Solubility(mg/ml) |
2.78E-02 |
Solubility(mol/l) |
5.36E-05 |
Class |
Moderately soluble |
Pharmacokinetics
GI absorbtion |
Low |
BBB permeant |
No |
Pgp substrate |
Yes |
CYP1A2 inhibitor |
No |
CYP2C19 inhibitor |
No |
CYP2C9 inhibitor |
No |
CYP2D6 inhibitor |
No |
CYP3A4 inhibitor |
Yes |
Log Kp (skin permeation) (cm/s) |
-7.69 |
Druglikeness
Lipinski Num. violations |
1 |
Ghose Num. violations |
3 |
Veber Num. violations |
0 |
Egan Num. violations |
1 |
Muegge Num. violations |
0 |
Bioavailability Score |
0.56 |
Medicinal Chemistry
PAINS Num. of alerts |
0 |
Brenk Num. of alerts |
0 |
Leadlikeness Num. of violations |
1 |
Synthetic Accessibility |
6.64 |
Biological Activity
Biological Activity |
JID |
Anticancer |
9 |